anti cd19 cd3 tetravalent antibody afm11

Drug Overview

The medication known as anti cd19 cd3 tetravalent antibody afm11 is an investigational, “next-generation” immunotherapy designed to treat aggressive B-cell malignancies, such as Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL). It belongs to a specialized class of drugs called T-cell engagers, which act as a molecular bridge between the patient’s immune system and the cancer cells.

Developed by Affimed N.V. using their proprietary TandAb® technology, AFM11 is a “tetravalent” antibody. While standard bispecific antibodies have two binding sites (one for the cancer and one for the immune cell), AFM11 has four binding sites: two for the CD19 protein on B-cells and two for the CD3 protein on T-cells. This increased “valency” is designed to create a much stronger and more stable connection, potentially leading to a more potent immune attack against the tumor.

• Generic Name: AFM11.
• Drug Class: Tetravalent Bispecific T-cell Engager (TandAb®).
• Target Antigens: CD19 and CD3.
• Route of Administration: Continuous Intravenous (IV) infusion.
• FDA Approval Status: Investigational/On Hold. As of March 2026, AFM11 is not FDA-approved. Clinical development was placed on a “clinical hold” after Phase I trials (NCT02106091 and NCT02848911) reported severe neurological side effects. While it remains a significant subject of research for its unique structure, it is not currently available for general clinical use.

What Is It and How Does It Work? (Mechanism of Action)

The Tetravalent Advantage

Most bispecific antibodies are small and have a short life in the body. AFM11 is a larger molecule (~105 kDa) with four binding arms. The two arms for CD19 allow it to grip the cancer cell with high “avidity” (strength), while the two arms for CD3 ensure it can activate T-cells even when the cancer cell’s markers are low.

Molecular Level Mechanisms

1. Dual Engagement: AFM11 circulates and binds simultaneously to CD19 on the B-cell leukemia or lymphoma cell and CD3 on a cytotoxic T-lymphocyte (killer T-cell).
2. Immunological Synapse: By bringing these cells together, the drug creates an artificial “synapse.” This proximity forces the T-cell to recognize the B-cell as an invader.
3. T-cell Activation: The binding to CD3 triggers the T-cell to release toxic granules containing perforins and granzymes.
4. Target Lysis: The perforins create holes in the cancer cell’s membrane, allowing granzymes to enter and trigger “programmed cell death” (apoptosis).
5. Serial Killing: Once the target cancer cell is destroyed, the T-cell can detach and, with the help of more AFM11, go on to kill other cancer cells.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for AFM11.

During its active clinical trials, it was investigated for:

• Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia (ALL): For adult patients who failed standard chemotherapy.
• Relapsed or Refractory Non-Hodgkin Lymphoma (NHL): Including Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma.

Dosage and Administration Protocols

Because AFM11 has a relatively short half-life compared to standard antibodies, it required a specific delivery method to maintain effective levels in the blood.

Clinical Efficacy and Research Results

The clinical journey of AFM11 provided critical data on the limits of T-cell engagement.

• Biological Activity: Early Phase I data showed that AFM11 was highly effective at depleting B-cells in the blood, proving that the tetravalent design successfully activated the immune system.
• Clinical Responses: Some patients in the ALL and NHL trials achieved complete remissions, even at very low doses.
• The Clinical Hold: In 2018, the trials were halted because three patients (one with ALL and two with NHL) experienced serious neurological adverse events, including one death. These events were determined to be “dose-limiting toxicities,” meaning the drug was too powerful for the brain to handle at the tested concentrations.

Safety Profile and Side Effects

The primary challenge with AFM11, like other CD3-engaging drugs, is managing the “over-activation” of the immune system.

Common Side Effects:

• Pyrexia (Fever) and Chills: Occurring as the immune system activates.
• Fatigue: A general sense of tiredness.
• Hypotension: Low blood pressure during the initial infusion.

Serious/Dose-Limiting Adverse Events:

• Neurotoxicity (ICANS): This was the most severe issue for AFM11. Symptoms included confusion, tremors, disorientation, and seizures.
• Cytokine Release Syndrome (CRS): A systemic inflammatory response characterized by high fever and organ dysfunction.
• Infections: Due to the drug killing both cancerous and healthy B-cells, patients were at higher risk for opportunistic infections.

Research Areas

In the field of Stem Cell and Regenerative Medicine, AFM11 is used as a model for studying “Blood System Resetting.” Researchers are investigating how to use tetravalent antibodies to completely clear out cancerous B-cells before a Stem Cell Transplant. The goal is to ensure that the patient’s “niche” in the bone marrow is entirely free of cancer so that new, healthy stem cells can regenerate a cancer-free immune system.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Neurological Baseline: Required to identify any pre-existing conditions that might increase the risk of neurotoxicity.
• B-cell Count: To measure the “tumor burden” before starting the infusion.
• Baseline Organ Function: Liver and kidney panels.

Precautions:

• Pump Management: Patients on continuous infusion must be trained on how to manage their portable pumps and avoid kinks in the tubing.
• Seizure Precautions: Due to the known risks, patients were often given anti-seizure medications during the first cycle.

“Do’s and Don’ts” List:

• DO report any “word-finding difficulties” or mild confusion immediately to your doctor.
• DO check the infusion pump regularly to ensure it is working correctly.
• DON’T drive or operate heavy machinery during the first two weeks of treatment due to the risk of sudden neurological changes.
• DON’T ignore a high fever, as it could be an early sign of a cytokine storm (CRS).

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. AFM11 is an investigational agent currently on clinical hold and is not FDA-approved. Always consult with a qualified oncologist regarding currently available and approved treatments for leukemia or lymphoma.